Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lactobacillus acidophilus + Bifidobacterium infantis + Enterococcus faecium
- Development stage
- Phase 2
- Lead developer
- Sandoz
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
A combination probiotic containing the bacterial strains *Lactobacillus acidophilus*, *Bifidobacterium infantis*, and *Enterococcus faecium*, marketed under the brand name Linex. This live biotherapeutic product is under investigation by Ain Shams University in a Phase 2 clinical trial (NCT06579066) for the treatment of uremic pruritus in non-dialysis chronic kidney disease (CKD) patients. The proposed mechanism of action is the modulation of the gut microbiome to reduce the production of uremic toxins, such as indoxyl sulfate, which are believed to contribute to pruritus. The study compares the efficacy of this oral capsule, given as an add-on therapy, against activated charcoal.
- Brand names
- Linex
- Other names
- probiotic blend-Ain Shams University-uremic pruritus
Beyond the preview
Go deeper on Lactobacillus acidophilus + Bifidobacterium infantis + Enterococcus faecium.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lactobacillus acidophilus + Bifidobacterium infantis + Enterococcus faecium.